摘要:
The present invention relates to compounds of formula (I) wherein X is N or P; —SO3— is —O—S(O)2— or —S(O)2—O—; and n and R1 to R5 are defined below, and to their use as additives for electrolyte compositions, in particular in electrolyte compositions for lithium batteries.
摘要:
Provided herein are compositions containing photoactivatable caged tamoxifen and tamoxifen derivative molecules. Also provided are kits containing one of these compositions and a light source. Also provided are methods of optically inducing nuclear translocation of a fusion protein containing a mammalian estrogen receptor ligand binding domain in a eukaryotic cell and methods of optically inducing recombination in a eukaryotic cell that include contacting a eukaryotic cell with at least one of these compositions. Also provided are methods of treating breast cancer in a subject that include administering a photoactivatable caged tamoxifen or tamoxifen derivative molecule to a subject having breast cancer.
摘要:
Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
摘要:
The present invention provides, inter alia, a compound having the structure: Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, and methods for treating or ameliorating the effects of a neurodegenerative disease.
摘要:
The invention provides compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.
摘要:
The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.
摘要:
The present invention relates to a para-aminophenol compound of formula (I), the addition salts thereof with an acid and the solvates thereof: in which: R represents a hydrogen or halogen atom; a C1-C4 alkyl radical; a carboxyl radical or a (C1-C4)alkoxycarbonyl radical; Z1 is an oxygen atom or a group NR2; R2 is a hydrogen atom or a linear or branched C1-C4 alkyl radical, a benzyl radical or an acetyl radical; R1 is a saturated, linear or branched C1-C10 alkyl radical, which is substituted with or interrupted by a cationic radical, optionally interrupted by one or more oxygen atoms and/or by one or more groups NR2, optionally substituted with one or more radicals chosen from hydroxyl, alkoxy or C1-C4 hydroxyalkyl radicals; or R1 is a saturated, unsaturated or aromatic cationic 5- to 8-membered heterocycle optionally substituted with one or more radicals chosen from C1-C4 alkyl, hydroxyl, C1-C4 alkoxy, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, thio, (C1-C4)alkylthio, carboxyl, (C1-C4)alkylcarbonyl, sulfonyl, amido or C1-C4 hydroxyalkyl radicals; and when Z1 represents NR2 then R1 and R2 may form, together with the nitrogen atom to which they are attached, a saturated or unsaturated cationic 5- to 8-membered heterocycle optionally substituted with one or more radicals chosen from C1-C10 alkyl radicals and hydroxyl, C1-C4 alkoxy, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, thio, (C1-C4)alkylthio, carboxyl, (C1-C4)alkylcarbonyl, sulfonyl, amido and C1-C4 hydroxyalkyl radicals, it being possible for this heterocycle to contain one or more heteroatoms chosen from N or O, preferably N; or R1 and R2 may form, together with the nitrogen atom to which they are attached, a saturated or unsaturated noncationic 5- to 8-membered heterocycle substituted with a cationic radical and optionally substituted with one or more radicals chosen from C1-C10 alkyl radicals and hydroxyl, C1-C4 alkoxy, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, thio, (C1-C4)alkylthio, carboxyl, (C1-C4)alkylcarbonyl, sulfonyl, amido and C1-C4 hydroxyalkyl radicals; An− represents an anion or a mixture of anions which are organic or inorganic and are cosmetically acceptable.
摘要:
Provided is a pharmaceutical composition for preventing or treating a cognitive impairment-related disease, the pharmaceutical composition including N-(2-hydroxyethyl)piperazine-N′(3-propane sulfonic acid), a pharmaceutically acceptable salt thereof or a derivative thereof, and donepezil, a pharmaceutically acceptable salt thereof or a derivative thereof. The composition may be used in preventing or treating a cognitive impairment-related disease.